EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study

A Iurlo, D Cattaneo, D Consonni, F Castagnetti, M C Miggiano, G Binotto, M Bonifacio, G Rege-Cambrin, M Tiribelli, F Lunghi, A Gozzini, P Pregno und 23 weitere

Frontiers in Pharmacology · 23.03.2023 · 14

DOI: 10.3389/fphar.2023.1154377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.03.2023. Verfasst von A Iurlo und 34 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However, data on its impact on successful treatment-free remission (TFR) are quite scarce. We conducted a retrospective study on the outcome of CML subjects who discontinued low-dose TKIs from 54 Italian hematology centers participating in the Campus CML network. Overall, 1.785 of 5.108 (35.0%) regularly followed CML patients were treated with low-dose TKIs, more frequently due to relevant comorbidities or AEs (1.288, 72.2%). TFR was attempted in 248 (13.9%) subjects, all but three while in deep molecular response (DMR). After a median follow-up of 24.9 months, 172 (69.4%) patients were still in TFR. TFR outcome was not influenced by gender, Sokal/ELTS risk scores, prior interferon, number and last type of TKI used prior to treatment cessation, DMR degree, reason for dose reduction or median TKIs duration. Conversely, TFR probability was significantly better in the absence of resistance to any prior TKI. In addition, patients with a longer DMR duration before TKI discontinuation (i.e., >6.8 years) and those with an e14a2 BCR::ABL1 transcript type showed a trend towards prolonged TFR. It should also be emphasized that only 30.6% of our cases suffered from molecular relapse, less than reported during full-dose TKI treatment. The use of low-dose TKIs does not appear to affect the likelihood of achieving a DMR and thus trying a treatment withdrawal, but might even promote the TFR rate.

Schlagwörter

Stichwörter der Autor:innen

chronic myeloid leukemialow doseoutcomeresistancetreatment-free remissiontyrosine kinase inhibitors

Autor:innen und Institutionen

  • Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Epidemiology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. and A. Seràgnoli", University of Bologna, "S. Orsola-Malpighi" Hospital, Bologna, Italy.
  • Division of Hematology, San Bortolo Hospital, Vicenza, Italy.
  • Department of Medicine, Hematology and Clinical Immunology, Padua School of Medicine, Padua, Italy.

Zitieren

APA

Iurlo, A., Cattaneo, D., Consonni, D., Castagnetti, F., Miggiano, M. C., Binotto, G., Bonifacio, M., Rege-Cambrin, G., Tiribelli, M., Lunghi, F., Gozzini, A., Pregno, P., Abruzzese, E., Capodanno, I., Bucelli, C., Pizzuti, M., Artuso, S., Iezza, M., Scalzulli, E., …, & Breccia, M. (2023). Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1154377

Vancouver

Iurlo A, Cattaneo D, Consonni D, Castagnetti F, Miggiano MC, Binotto G, et al. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1154377

BibTeX
@article{Iurlo2023,
  author = {Iurlo, A and Cattaneo, D and Consonni, D and Castagnetti, F and Miggiano, M C and Binotto, G and Bonifacio, M and Rege-Cambrin, G and Tiribelli, M and Lunghi, F and Gozzini, A and Pregno, P and Abruzzese, E and Capodanno, I and Bucelli, C and Pizzuti, M and Artuso, S and Iezza, M and Scalzulli, E and La Barba, G and Maggi, A and Russo, S and Elena, C and Scortechini, A R and Tafuri, A and Latagliata, R and Caocci, G and Bocchia, M and Galimberti, S and Luciano, L and Fava, C and Foà, R and Saglio, G and Rosti, G and Breccia, M},
  title = {Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1154377}
}
Kostenlos starten →